VivoSeq
Other

Single Ventricle

7

Pipeline Programs↗

1

Active Trials↗

5

Companies Involved↗

Single ventricle is an early-stage landscape with 7 programs across 5 companies. The most active players are Jazz Pharmaceuticals, Johnson & Johnson, Gilead. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

0/100

Mech. Concentration

40/100

Completion Rate

91/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2Gilead logo

Gilead

1 program

Phase 2Pfizer logo

Pfizer

1 program

ApprovedUnited Therapeutics logo

United Therapeutics

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

91%

Small molecule

10 of 11 classified programs — the dominant modality here.

9%ALL OTHERSCell therapy19%

Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.

Analysis

Trial Status

13

clinical trials

Completed10 · 77%
Terminated1 · 8%
Recruiting1 · 8%
Unknown status1 · 8%

Clinical Trials

Trial Activity

13 trials

IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease
Recruiting·—·Phase 1·NCT06324396·15 enrolled
Liothyronine in Children With Single Ventricle Congenital Cardiac Malformations Undergoing the Fontan Procedure
Completed·FFDA Office of Orphan Products Development·Phase 1·NCT00004828·28 enrolled
Bosentan Therapy in Children With Functional Single Ventricle
Completed·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT01662037·34 enrolled
Study of Placebo or Bosentan to Treat Patients With Single Ventricle Physiology.
Completed·—·Phase 2·NCT01292551·75 enrolled
Endothelin Blockade in Patients With Single Ventricle Physiology
Completed·UUniversity of California, Los Angeles·N/A·NCT00989911·10 enrolled
Spironolactone in Patients With Single Ventricle Heart
Completed·EEmory University·N/A·NCT00211081·12 enrolled
Trial of Angiotensin Converting Enzyme Inhibition in Infants With Single Ventricle--Pediatric Heart Network
Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00113087·230 enrolled
Ambrisentan in Single Ventricle
Completed·—·Phase 2·NCT02080637·16 enrolled
Sildenafil in Single Ventricle Patients
Completed·—·Phase 1·NCT01169519·21 enrolled
Acute Imposition of Fontan Physiology in The Single Ventricle Patient: Effects on Fibrosis, Function and Drug Intervention
Completed·CChildren's Hospital of Philadelphia·Preclinical·NCT04901975·98 enrolled
RE-ENERGIZE FONTAN: A RandomizEd Exercise INtERvention DesiGned to MaximIZE Fitness in Pediatric FONTAN Patients
Completed·SStanford University·Preclinical·NCT04195451·150 enrolled
Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery
Terminated·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 1·NCT01161641·5 enrolled
Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle
Unknown status·—·Phase 1/2·NCT03079401·19 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)